[ad_1]
The total of 103 deaths reported since Thursday morning include 43 in Maharashtra; 29 in Gujarat; eight in Madhya Pradesh; seven in West Bengal; five in Rajasthan; two each in Tamil Nadu, Uttar Pradesh and Andhra Pradesh; and one in Bihar, Delhi, Karnataka, Punjab and Jammu and Kashmir.
Up to five people were taken to the isolation ward of the Aluva District Hospital after they were found to have symptoms of Covid-19. These people were among the 181 Kerala natives who were brought in from Abu Dhabi last night. Meanwhile, Mumbai has made arrangements for citizens returning home after being stranded abroad for more than a month after the shutdown. The Brihanmumbai Municipal Corporation (BMC) has reserved 3,343 rooms at 88 hotels in Mumbai to quarantine the Indians who will be returned on seven flights.
In Gujarat, Cadila Pharmaceuticals, one of the country’s largest private pharmaceutical companies, closed its formulation manufacturing plant in Ahmedabad on Thursday after more than two dozen of its employees tested positive for the new coronavirus.
A senior government official said Thursday night that five employees had tested positive for COVID-19 six days ago, while another 21 tested positive this week.
“We had collected samples from 30 Cadila employees on May 5, and 21 of the samples tested positive the day after,” said Arun Mahesh Babu, the Ahmedabad District Development Officer.
He added that the plant was ordered closed Thursday, 95 employees were quarantined and disinfection work began at the site.
The incident comes just days after India began easing some of its blocking restrictions aimed at preventing the spread of the new coronavirus. Ahmedabad, however, is one of the hardest hit cities in India and has moved to tighten restrictions this week.
In a statement, Cadila Pharmaceuticals said: “Recently, 26 of our employees at our Dholka manufacturing plant tested positive for COVID-19. After this, we have closed our operations on our own.”
The company also said it is cooperating with the local administration to ensure the safety of its facilities and surroundings.
In addition to Dholka, Cadila Pharmaceuticals has manufacturing facilities in other parts of India and Ethiopia. The company is a major producer of Active Pharmaceutical Ingredients (APIs), the key ingredients used in the manufacture of a drug.
.
[ad_2]
